Cybin to acquire Small Pharma in a previously announced all-share transaction expected to close in Q4, “creating an international clinical-stage leader in novel psychedelic therapeutics with the largest IP portfolio in the secor.” Results suggest that SSRIs enhance the efficacy of SPL026 DMT when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs , At Week 4, 100% of patients in the SSRI cohort responded to SPL026 or DMT, with 92% of patients in remission from depression ….also no apparent differences in the safety and tolerability profile of SPL026 following administration to participants in the SSRI and non-SSRI patient cohorts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYBN:
- Cybin announces agreement with Fluence to support scaling of Embark training
- Cybin completes enrollment in CYB003 study
- Cybin announces grant of U.S. patent covering deuterated tryptamines
- Cybin price target lowered to C$1 from C$1.50 at Stifel
- Cybin acquisition bodes well for value creation, says Cantor Fitzgerald
